Opendata, web and dolomites

Magicbullet Reloaded SIGNED

Small-Molecule Drug Conjugates for Targeted Delivery in Tumor Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Magicbullet Reloaded project word cloud

Explore the words cloud of the Magicbullet Reloaded project. It provides you a very rough idea of what is the project "Magicbullet Reloaded" about.

organism    pharmacokinetic    premature    magic    nobel    scientific    ehrlich    array    grant    expanded    magicbullet    organic    worldwide    consequence    refers    conjugates    resistance    peptide    642004    bold    complementarity    therapy    immune    drugs    drug    chemistry    acquired    synthesize    successful    esrs    biochemistry    physiology    death    title    competences    efforts    implication    1908    stimulate    expand    agent    special    exposed    efficient    therapeutic    investigation    industry    idea    delivered    antitumor    expert    causing    selectivity    pharmacology    biology    basis    bullet    tissue    tumor    etn    brings    recruited    interdisciplinary    substantially    discovery    paul    faceted    2018    reloaded    outstanding    ideal    pdcs    laureate    immuno    kills    cancer    treatments    direction    pipeline    medicinal    molecule    versa    broad    overcome    academia    cell    had    continuing    compound    perfectly    made    environment    antigens    2015    builds    smdcs    small    vision    disease    cells    toxin    despite    selectively    vice   

Project "Magicbullet Reloaded" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAET BIELEFELD 

Organization address
address: UNIVERSITAETSSTRASSE 25
city: BIELEFELD
postcode: 33615
website: www.uni-bielefeld.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙915˙902 €
 EC max contribution 3˙915˙902 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2023-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAET BIELEFELD DE (BIELEFELD) coordinator 252˙788.00
2    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 303˙172.00
3    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) participant 281˙276.00
4    PHILOCHEM AG CH (OTELFINGEN) participant 281˙276.00
5    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 280˙805.00
6    EXIRIS SRL IT (ROMA) participant 261˙499.00
7    TAKIS SRL IT (ROMA) participant 261˙499.00
8    UNIVERSITA DEGLI STUDI DELL'INSUBRIA IT (VARESE) participant 261˙499.00
9    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) participant 261˙499.00
10    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 252˙788.00
11    HEIDELBERG PHARMA RESEARCH GMBH DE (LADENBURG) participant 252˙788.00
12    TECHNISCHE UNIVERSITAT DARMSTADT DE (DARMSTADT) participant 252˙788.00
13    UNIVERSITAET ZU KOELN DE (KOELN) participant 252˙788.00
14    EOTVOS LORAND TUDOMANYEGYETEM HU (BUDAPEST) participant 229˙715.00
15    Orszagos Onkologiai Intezet HU (Budapest) participant 229˙715.00

Map

 Project objective

'Despite the continuing development of new and more efficient treatments, cancer remains the second cause of premature death worldwide. Multi-faceted interdisciplinary research efforts in industry and academia on different aspects of cancer have provided a knowledge basis for the development of novel therapeutic approaches. Paul Ehrlich, Nobel laureate in Physiology of 1908, had the early vision that a compound could be made to selectively target a disease-causing organism or tumor. A toxin for the particular tissue could be delivered by an agent of selectivity. Such an ideal therapeutic agent would be a 'magic bullet' that only kills the target cells. This ETN initiative with the title Magicbullet::reloaded refers to Ehrlich’s bold idea and builds on the previous experience of the highly successful ETN MAGICBULLET (2015-2018, grant agreement No. 642004). As a consequence of the outstanding results, the ETN Magicbullet::reloaded will expand the field of investigation from peptide-drug conjugates (PDCs) to small molecule-drug conjugates (SMDCs) with a special focus on drugs capable to stimulate tumor immune responses and overcome resistance to immuno-therapy. The consortium has been substantially expanded to perfectly address the needs of the new research direction. The planned ETN will design and synthesize an array of SMDCs (including PDCs), also targeting less investigated tumor antigens, investigate their pharmacokinetic behaviour, their implication on the immune system, as well as their tumor selectivity and antitumor activity. The consortium brings together interdisciplinary expert knowledge in Organic Chemistry, Peptide Chemistry, Medicinal Chemistry, Drug Discovery, Biochemistry, Pharmacology and Cell Biology. This high complementarity is required for the different scientific tasks in the development pipeline. Vice versa, the recruited ESRs will be exposed to a challenging research environment leading to a broad range of scientific competences to be acquired.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGICBULLET RELOADED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGICBULLET RELOADED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SuperCol (2020)

SuperCol: Rational design of super-selective and responsive colloidal particles for biomedical applications

Read More  

EAGRE (2020)

Eagre/Aegir: high-seas wave-impact modelling

Read More  

ApPEARS (2019)

Appearance Printing - European Advanced Research School

Read More